Optune Pax
Novocure, GmbH · Decision date Oct 26, 2026
What did the FDA decide?
FDA recorded decision OK30 on 2026-10-26 for Optune Pax under PMA P250034, supplement S004, a 30-Day Notice filed under the reason "Process Change - Manufacturer/Sterilizer/Packager/Supplier." The stated purpose is "approval for changes to the sterilization load configuration." The source does not identify which sterilizer, facility, load size, cycle, or validated parameters changed, so the specific configuration change cannot be described beyond that label.
The P250034 identifier indicates this action amends the existing PMA rather than granting a new approval of the whole system. The record lists the device category as Low Electric Field Generator for Pancreatic Cancer Treatment with product code SHC; the supplement's stated purpose concerns sterilization load configuration, which is a manufacturing matter. That reported purpose is not independent proof of safety or clinical effectiveness, and no new indication should be inferred.
FDA approval order statement
approval for changes to the sterilization load configuration.
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- General, Plastic Surgery
- Decision date
- Oct 26, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P250034/S004
- Regulatory pathway
- PMA supplement
- Applicant
- Novocure, GmbH
- Product code
- SHC
- Decision code
- OK30
- Decision date
- Oct 26, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Low Electric Field Generator for Pancreatic Cancer Treatment.
- Applicant
- Novocure, GmbH
- Product code
- SHC
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P250034. Subsequent supplements may change the device or its indications.
FDA decision timeline
P250034 · Original PMA
Optune Pax
P250034/S004 received
Application receipt date recorded by FDA.
P250034/S004 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P250034. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P250034
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Optune PaxP250034 | Novocure, GmbH | PMA approval | Feb 11, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Novocure, GmbH
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Neuhofstrasse 21, Baar, 6340
Sources and methodology
- Original FDA record: P250034/S004
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records